Answers are grounded in this paper and cite their sources.
Dyspnea is a critical component of chronic obstructive pulmonary disease (COPD). We report the effect of ensifentrine, a novel PDE3/PDE4 inhibitor, on dyspnea using pooled data from the Phase 3 ENHANCE-1/2 trials.
No takes yet. Share an insight, caveat, or question.
Mahler et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: